Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.75 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach regarding future expectations. They emphasized the importance of their clinical pipeline.
Management did not provide specific revenue guidance for the upcoming quarter.
The focus remains on ongoing clinical trials and product development.
Madrigal Pharmaceuticals reported a loss of $0.75 per share, which was in line with expectations, though no revenue figures were disclosed. The stock reacted negatively, declining by 0.51%. Investors may be concerned about the lack of guidance and the company's focus on clinical trials, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BWX TECHNOLOGIES INC
Feb 25, 2019